Chemical compounds

Furandicarboxylic Acid (FDCA) Market to Witness Steady Growth Based on Increasing Demand for Carbonated Soft Drink Till 2020 | Million Insights

Retrieved on: 
Monday, December 9, 2019
Carboxylic acids, Furans, 2,5-Furandicarboxylic acid, Chemical compounds, FDCA, Acid, Alkanoic acids, Fatty acids

Furandicarboxylic acid is a carbon-based chemical complex containing two groups of carboxylic acids attached to a principal furan circle.

Key Points: 
  • Furandicarboxylic acid is a carbon-based chemical complex containing two groups of carboxylic acids attached to a principal furan circle.
  • Get Sample PDF and read more details about the "Furandicarboxylic Acid (FDCA) Market" Report 2020.
  • The increasing demand from the market for carbonated soft drink is one of the principal features motivating the development of the furandicarboxylic acid market.
  • Browse 80 page research report with TOC on "Global Furandicarboxylic Acid (FDCA) Market" at: https://www.millioninsights.com/industry-reports/furandicarboxylic-acid-...
    FDCA Potential Application Outlook (Volume, Tons; Revenue, USD Million, 2012 - 2020)

BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

Retrieved on: 
Monday, December 9, 2019
Clinical medicine, Medicine, Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, Biomarkers, AXL receptor tyrosine kinase, Bemcentinib, 7+3, CD135, Midostaurin

The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efficacy among both newly diagnosed and relapsed/refractory AML patients.

Key Points: 
  • The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efficacy among both newly diagnosed and relapsed/refractory AML patients.
  • Pretreatment sAXL holds as a predictive biomarker in AML patients treated with the combination, and a new novel blood based predictive biomarker is identified and associated with clinical benefit in AML and Lung cancer patients receiving bemcentinib.
  • The duration of response and successful treatment beyond progression are consistent with the previously reported immunomodulatory activity of bemcentinib.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

Retrieved on: 
Monday, December 9, 2019
Chemical compounds, Tyrosine kinase receptors, Protein kinase inhibitors, AXL receptor tyrosine kinase, Heterocyclic compounds, Bemcentinib, Organic compounds, Lactams, CD135

The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efficacy among both newly diagnosed and relapsed/refractory AML patients.

Key Points: 
  • The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efficacy among both newly diagnosed and relapsed/refractory AML patients.
  • The duration of response and successful treatment beyond progression are consistent with the previously reported immunomodulatory activity of bemcentinib.
  • The current data further highlight the novel tumor-immune effects of bemcentinib observed in previous cohorts and in other cancer types.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Sunday, December 8, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Chemical compounds, Breakthrough therapy, Organic compounds, Tyrosine kinase inhibitors, Acrylamides, Ibrutinib, Piperidines, Pyrazolopyrimidines, Bruton's tyrosine kinase, Clinical medicine

All patients (23/23) had received prior ibrutinib and most (21/23) were refractory to or had relapsed on the BTK inhibitor.

Key Points: 
  • All patients (23/23) had received prior ibrutinib and most (21/23) were refractory to or had relapsed on the BTK inhibitor.
  • Patients received liso-cel target doses of either 50 106 (n=9) or 100 106 (n=14) CAR+ T cells following lymphodepletion.
  • Seventy-four percent (17/23) of patients had cytokine release syndrome (CRS) of any grade with 9% of patients (2/23) experiencing grade 3 CRS.
  • Thirty-nine percent (9/23) of patients had neurological events (NE) of any grade, while 22% (5/23) of patients had grade 3 or higher NE.

TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Sunday, December 8, 2019
Chemical compounds, RTT, Organic compounds, Breakthrough therapy, Genentech, Chronic lymphocytic leukemia, Venetoclax, Umbralisib, Leukemia, CLL, Obinutuzumab

Data from this trial were presented this morning during an oral session at the 61st American Society of Hematology(ASH) Annual Meeting and Exposition.

Key Points: 
  • Data from this trial were presented this morning during an oral session at the 61st American Society of Hematology(ASH) Annual Meeting and Exposition.
  • We look forward to updating these data at future conferences as more patients are followed for 12 months and longer.
  • Mr. Weiss continued, We were also excited to see that 87% of patients responded to the U2 combination after just three months of treatment prior to the introduction of venetoclax.
  • Title: A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    This oral presentation includes data from patients with relapsed or refractory CLL treated with the triple combination of ublituximab, umbralisib, and venetoclax.

Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting

Retrieved on: 
Sunday, December 8, 2019
Chemical compounds, Antineoplastic drugs, Pyrazines, Selinexor, Teratogens, Triazoles, XPO1, Chemistry, Electrolyte disturbances, Branches of biology, Hyponatremia, Karyopherin

XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).

Key Points: 
  • XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).
  • Selinexor has received Fast Track designation from the FDA for the patient population evaluated in the SADAL study.
  • XPOVIO can cause hyponatremia; 39% of patients treated with XPOVIO experienced hyponatremia, 22% of patients experienced Grade 3 or 4 hyponatremia.
  • For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO; that regulators will agree that selinexor qualifies for conditional approval in the E.U.

New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Retrieved on: 
Sunday, December 8, 2019
Chemical compounds, RTT, Drugs, Cancer treatments, Genentech, Breakthrough therapy, Specialty drugs, Chronic lymphocytic leukemia, Bendamustine, Rituximab, Venetoclax, Chemotherapy regimen

"The sustained efficacy and manageable safety profile observed in the study further supportthe clinical benefits of fixed treatment in patients with relapsed or refractory chronic lymphocytic leukemia."

Key Points: 
  • "The sustained efficacy and manageable safety profile observed in the study further supportthe clinical benefits of fixed treatment in patients with relapsed or refractory chronic lymphocytic leukemia."
  • The trial was designed to evaluate the efficacy and safety of venetoclax in combination with rituximab (n=194) compared with bendamustine in combination with rituximab (n=195).
  • The median age of patients in the trial was 65 years (range: 22 to 85).3
    The primary efficacy endpoint was INV-assessed PFS.
  • Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL).

Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting

Retrieved on: 
Saturday, December 7, 2019
Chemical compounds, Medicine, Clinical medicine, Antineoplastic drugs, Pyrazines, Selinexor, Teratogens, Triazoles, XPO1, Thrombocytopenia, Diffuse large B-cell lymphoma, Lymphoma

XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).

Key Points: 
  • XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).
  • Selinexor is also being studied in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • Selinexor has received Fast Track designation from the FDA for the patient population evaluated in the SADAL study.
  • Thrombocytopenia was reported as an adverse reaction in 74% of patients, and severe (Grade 3-4) thrombocytopenia occurred in 61% of patients treated with XPOVIO.

Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

Retrieved on: 
Saturday, December 7, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Medicine, Cancer, RTT, Duvelisib, Oncology, Verastem Oncology, Chronic lymphocytic leukemia, Venetoclax, Leukemia, Phosphoinositide 3-kinase inhibitor, P110δ, COPIKTRA, Verastem Oncology

The results of the trial also identified the optimal dosing regimen for future clinical study, said Brian Stuglik, Chief Executive Officer of Verastem Oncology.

Key Points: 
  • The results of the trial also identified the optimal dosing regimen for future clinical study, said Brian Stuglik, Chief Executive Officer of Verastem Oncology.
  • The PRIMO study is a multi-center, open-label, registration-directed Phase 2 study evaluating duvelisib in patients with relapsed or refractory PTCL that is expected to enroll approximately 120 patients.
  • Serious AEs occurring in 2 patients were colitis, diarrhea, abdominal pain, pyrexia, sepsis, pneumonia, hyponatremia, rash/maculopapular, dyspnea, and respiratory failure.
  • Another key presentation at the meeting highlights new data from an investigator-sponsored Phase 1 study exploring duvelisib in combination with venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia

Retrieved on: 
Saturday, December 7, 2019
RTT, Drugs, Chemical compounds, Organic compounds, Breakthrough therapy, Tyrosine kinases, Acrylamides, Ibrutinib, Bruton's tyrosine kinase, Chronic lymphocytic leukemia, Rituximab, Leukemia

During this extended follow-up, IMBRUVICA was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.

Key Points: 
  • During this extended follow-up, IMBRUVICA was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.
  • These new findings from the E1912, RESONATE/RESONATE-2 and CAPTIVATE studieswere presented at the 2019 American Society of Hematology (ASH) Annual Meeting.
  • OS benefit also continued to favor the IMBRUVICA plus rituximab arm (HR, 0.34; 95 percent CI, 0.15-0.79; p=0.009).
  • The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.